May 28, 2016
Edinburgh, UK

Solid at the 8th Annual ECRD Meeting

In May, Solid had the honor of participating in the 8th European Conference on Rare Diseases & Orphan Products in Edinburgh, which is organized bi-annually by the European Organisation for Rare Diseases (EURODIS) and DIA Europe, Middle East & Africa.

ECRD is one of the foremost meetings of the rare disease community, offering those impacted by rare diseases and those committed to solving them with the opportunity to share ideas, concerns and progress.

During the meeting, Carl Morris, Ph.D., Solid’s vice president of Research & Development, showcased why Solid fits naturally into the conference’s theme of “Game Changers in Rare Disease.”  During a panel discussion called “Launch Platforms,” Dr. Morris discussed Solid’s unique business model that focuses solely on solving Duchenne muscular dystrophy, regardless of technology or modality. Dr. Morris also discussed our novel strategies to partner with the community and develop tested collaborations. 

“It is through working together, sharing our learnings and progress, and listening to the experiences of others that we will be successful in our goal to address all facets of Duchenne muscular dystrophy and improve the quality of life for those impacted by the disease,” said Dr. Morris.

To learn more about our approach to therapy and assistive device development,

Click Here

Related news


Synpromics Ltd, the leader in gene control, today announces a new research partnership with Solid Biosciences, LLC. 


New data from the SGT-001 preclinical program was published today in Molecular Therapy – Methods and Clinical Development

  • Jennifer Ziolkowski, CPA, joins as Chief Financial Officer.
  • Carl Morris, Ph.D., promoted to Chief Scientific Officer.
  • Joel Schneider, Ph.D., promoted to Chief Technology Officer, Head of Exploratory R&D.

Company to Use Proceeds to Advance Programs for Duchenne Muscular Dystrophy.


Solid Biosciences is proud to join the global Rare Disease community to recognize Rare Disease Day 2017.


As we move into 2017, I want to reflect on our journey since founding Solid three years ago and to outline what we hope to accomplish in the coming year.


The Duchenne Research Fund (DRF) provided Solid with a research grant of $600,000 to support its LTBP4 program to combat fibrosis and to support novel biomarker work in Duchenne muscular dystrophy (DMD).


Grant from Duchenne UK to fund research to better understand the potential benefits of statins in patients with Duchenne muscular dystrophy (DMD).


Biologic candidate has the potential to complement gene therapy by improving muscle function.


It has been an exciting and emotional time for our Duchenne muscular dystrophy (DMD) community.


More information about Solid?

Please subscribe to receive our latest news